FDA “Breakthrough Therapy” Designations
Breakthrough status was introduced in FDASIA to facilitate development and review for drugs to treat serious/life-threatening diseases where there is early evidence of a substantial improvement over existing therapies. FDA has not yet released details on the program, but 11 requests have been granted.
You may also be interested in...
Parliamentary debate next week on the post-Brexit regulatory adjustments ahead for the UK medical devices industry will coincide with the opening of post-Brexit EU trade talks by the UK government. After a period of nervous calm, Brexit will be back with a bang.
Europe’s Innovative Medicines Initiative is to get €90m in funding for programs targeting the coronavirus outbreak.